Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Oral progestagens before menopause and breast cancer risk.

Fabre A, Fournier A, Mesrine S, Desreux J, Gompel A, Boutron-Ruault MC, Clavel-Chapelon F.

Br J Cancer. 2007 Mar 12;96(5):841-4.

2.

Progestagens use before menopause and breast cancer risk according to histology and hormone receptors.

Fabre A, Fournier A, Mesrine S, Gompel A, Desreux J, Berrino F, Boutron-Ruault MC, Romieu I, Clavel-Chapelon F.

Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2723-8. doi: 10.1158/1055-9965.EPI-08-0056.

3.

Progestagen-only treatment before menopause: increased risk of breast cancer.

[No authors listed]

Prescrire Int. 2008 Dec;17(98):243.

PMID:
19422175
4.

Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.

van Leeuwen FE.

Acta Endocrinol (Copenh). 1991;125 Suppl 1:13-26. Review.

PMID:
1801500
5.

Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study.

Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E.

Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1375-81.

6.

Estrogen-progestagen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks?

Fournier A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F.

J Clin Oncol. 2009 Nov 1;27(31):5138-43. doi: 10.1200/JCO.2008.21.6432.

PMID:
19752341
7.

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.

Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE.

N Engl J Med. 1995 Jun 15;332(24):1589-93.

8.

Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study.

Fournier A, Berrino F, Clavel-Chapelon F.

Breast Cancer Res Treat. 2008 Jan;107(1):103-11. Erratum in: Breast Cancer Res Treat. 2008 Jan;107(2):307-8.

9.

Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study.

Colditz GA, Stampfer MJ, Willett WC, Hunter DJ, Manson JE, Hennekens CH, Rosner BA, Speizer FE.

Cancer Causes Control. 1992 Sep;3(5):433-9.

PMID:
1525324
10.
11.

[Characteristics and determinants of initiation of premenopausal use of oral progestagens in the French E3N cohort].

Fabre A, Fournier A, Mesrine S, Ringa V, Clavel-Chapelon F.

J Gynecol Obstet Biol Reprod (Paris). 2010 Jun;39(4):310-7. doi: 10.1016/j.jgyn.2010.03.011. French.

12.

Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.

Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F.

J Clin Oncol. 2008 Mar 10;26(8):1260-8. doi: 10.1200/JCO.2007.13.4338.

13.

Progestogen use in women approaching the menopause and breast cancer risk.

Campagnoli C, Ambroggio S, Lotano MR, Peris C.

Maturitas. 2009 Apr 20;62(4):338-42. doi: 10.1016/j.maturitas.2008.10.017. Review.

PMID:
19118958
14.

Oral contraceptive use and risk of breast cancer in older women (New Zealand).

Paul C, Skegg DC, Spears GF.

Cancer Causes Control. 1995 Nov;6(6):485-91.

PMID:
8580295
15.

The risk of breast cancer after estrogen and estrogen-progestin replacement.

Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C.

N Engl J Med. 1989 Aug 3;321(5):293-7.

PMID:
2546079
16.

Postmenopausal estrogen and progestin use in relation to breast cancer risk.

Newcomb PA, Titus-Ernstoff L, Egan KM, Trentham-Dietz A, Baron JA, Storer BE, Willett WC, Stampfer MJ.

Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):593-600.

17.

Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study.

Gauthier E, Paoletti X, Clavel-Chapelon F; E3N group..

Hum Reprod. 2004 Oct;19(10):2216-21.

18.

Oral contraceptive agents and breast cancer: a population-based case-control study.

Rohan TE, McMichael AJ.

Med J Aust. 1988 Nov 21;149(10):520-6.

PMID:
3185321
19.

Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease.

Plu-Bureau G, Lê MG, Sitruk-Ware R, Thalabard JC, Mauvais-Jarvis P.

Br J Cancer. 1994 Aug;70(2):270-7.

20.

Oral contraceptives and breast cancer: latest findings in a large cohort study.

Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D.

Br J Cancer. 1989 Apr;59(4):613-7.

Items per page

Supplemental Content

Support Center